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We analyzed four families that presented with a
similar condition characterized by congenital micro-
cephaly, intellectual disability, progressive cerebral
atrophy, and intractable seizures. We show that
recessive mutations in the ASNS gene are respon-
sible for this syndrome. Two of the identified
missense mutations dramatically reduce ASNS
protein abundance, suggesting that the mutations
cause loss of function. Hypomorphic Asns mutant
mice have structural brain abnormalities, includingenlarged ventricles and reduced cortical thickness,
and show deficits in learning and memory mimicking
aspects of the patient phenotype. ASNS encodes
asparagine synthetase, which catalyzes the synthe-
sis of asparagine from glutamine and aspartate.
The neurological impairment resulting from ASNS
deficiencymay be explained by asparagine depletion
in the brain or by accumulation of aspartate/gluta-
mate leading to enhanced excitability and neuronal
damage. Our study thus indicates that asparagine
synthesis is essential for the development and func-
tion of the brain but not for that of other organs.Neuron 80, 429–441, October 16, 2013 ª2013 Elsevier Inc. 429
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Intellectual disability (ID) affects 2%–3% of the general popula-
tion and is characterized by a broad range of cognitive deficits.
It is usually subdivided into syndromic and nonsyndromic forms,
depending on whether additional abnormalities are found. Syn-
dromic ID is often accompanied by microcephaly, defined by a
head circumference more than two SDs below the age- and
sex-adjusted mean. The incidence of microcephaly, as reported
in birth defect registries world-wide, varies from 1 to 150 per
100,000 depending upon the range of SD used to define micro-
cephaly and the ethnic population. For example, microcephaly is
more prevalent in populations with a high degree of consanguin-
ity (Mahmood et al., 2011). Causes of congenital microcephaly
includemetabolic disorders, chromosomal anomalies, and intra-
uterine infections. However, with the exception of autosomal
recessive primary microcephaly (MCPH), the genetic etiology
of most congenital microcephaly cases is unknown.
We ascertained four families with a distinct form of severe
encephalopathy associated with congenital microcephaly and
progressive brain atrophy. Two families were from the same
ethnic group, whereas the other two families were independently
recognized as presenting with an identical syndrome. Both pairs
of families were analyzed independently by exome sequencing.
Here we report the clinical features of the affected children and
demonstrate that the observed phenotype in all four families
can be explained by autosomal recessive deficiency of aspara-
gine synthetase (ASNS).
RESULTS
Identification and Validation of ASNS Mutations
We identified a total of nine children from four families with a
severe form of intellectual disability (Table 1; Figure 1A; Supple-
mental Experimental Procedures available online). These chil-
dren were born with a small head circumference and showed
progressive microcephaly. Although congenital microcephaly
is a consistent feature of this syndrome, the patients do not fit
the definition of primary microcephaly (MCPH) (Supplemental
Experimental Procedures). Their clinical course was character-
ized by profound developmental delay and, in a majority of
cases, early-onset intractable seizures (Table 1; Figure 2; Fig-
ure S1). Clinical examination revealed axial hypotonia with
severe appendicular spasticity in all cases. All affected siblings
of family C also showed excessive startle reflex, mimicking
hyperekplexia. In addition, several affected individuals from fam-
ilies C and D had episodes of hypothermia. Brain MRI first per-
formed in early infancy showed decreased cerebral volume
and size of pons, presumably caused by hypodevelopment
and/or atrophy, as well as delayed myelination (Figure 2; Fig-
ure S1). Some patients also showed gyral simplification. The
affected children from two families (C and D) died during the first
year of life because of pulmonary aspiration secondary to severe
neurological dysfunction, whereas the affected individuals from
the other families survived into their third decade.
Families A and B are unrelated but are both of Iranian Jewish
ancestry. Targeted exonic regions were captured and
sequenced in one affected individual from family A (A.II.1) and430 Neuron 80, 429–441, October 16, 2013 ª2013 Elsevier Inc.two from family B (B.II.2 and B.II.4). We focused on variants
that were annotated as having a plausible impact on the function
of the resulting gene product (e.g., missense, nonsense, splice
site, intron-exon boundary, and coding-disrupting insertion-
deletions [indels]). We compared patient exomes to control
exomes sequenced in the same facility (n = 261, unrelated sam-
ples, not enriched for neurological disorders). Because families A
and B belong to the same ethnic community and were the only
similar cases identified in Israel to date, we postulated that the
causal variant would be a founder mutation in this population
shared among all affected individuals in these families.We there-
fore first focused on homozygous variants that were shared by
both siblings in family B (Figure 1A, B.II.2 and B.II.4) and that
were uncommon in our control population (Table S1). Since the
incidence of this disorder is very low in the general population,
we inspected only variants with a predicted frequency of %3%
in our sequenced control genomes. We found 72 such variants,
only three of which were absent in the control population (Table
S2). Furthermore, only one of these three variants was also pre-
sent in homozygous form in the patient from family A (Figure 1A,
A.II.1). This variant, located in the asparagine synthetase (ASNS)
gene, causes a missense change (c.1084T > G) resulting in a
phenylalanine to valine substitution at amino acid position 362
(p.F362V; NM_183356). We also performed homozygosity map-
ping. We found that p.F362V lies in the largest homozygous
region and found no additional candidates of interest in the
homozygous regions (Supplemental Experimental Procedures;
Tables S7–S9).
Family C is composed of three affected (C.II.1, C.II.3, and
C.II.4) siblings and one healthy (C.II.2) sibling born to consan-
guineous parents of Bangladeshi origin (Figure 1A). No DNA
was available for the first affected child (C.II.1) who had the
same clinical manifestations as his affected brothers. Homozy-
gosity mapping showed that the two affected siblings share a
total of eight homozygous regions that are >1 Mb in size (Table
S3). Exome sequencing performed in one of the affected chil-
dren (C.II.3) identified 856 rare protein or splice-altering variants
(with a frequency %3% in 169 in-house unrelated exomes,
1,000 Genomes Project data set and data from the National
Heart, Lung, and Blood Institute [NHLBI] Exome Sequencing
Project [ESP]). These included three variants that map to the
shared regions of homozygosity; the three variants were Sanger
sequenced and all three variants were homozygous in both
affected individuals. The parents and the unaffected sibling
were heterozygous for two of these variants, whereas the other
candidate variant was excluded from further consideration
because it was found in a homozygous form in one of the par-
ents. One of the remaining variants, c.1282G > A (p.D428N;
NM_017460) in the CYP3A4 gene, is not predicted to affect pro-
tein function by SIFT or Polyphen-2 (Adzhubei et al., 2010; Ng
and Henikoff, 2003) and CYP3A4 encodes a component of
cytochrome P450 (subfamily 3A, polypeptide 4), which is pre-
dominantly expressed in the liver. Thus, the CYP3A4 variant
seemed unlikely to be responsible for this phenotype. The
sole remaining variant in this family is c.1648C > T (p.R550C;
NM_183356) in ASNS, which is present in the largest region
of homozygosity (35 Mb) shared by the two affected children
(Table S4).
Table 1. Clinical Features of Patients with Mutations in ASNS
Family A Family B Family C Family D
Consanguinity Yes No Yes No
Ethnic origin Iranian Jews Iranian Jews Bangladeshi French Canadian
Subjects A.II.1 B.II.2 B.II.4 C.II.1 C.II.3 C.II.4 D.II.1 D.II.2 D.II.3
Genotype p.F362V/p.F362V p.F362V/p.F362V p.F362V/p.F362V Not determined p.R550C/
p.R550C
p.R550C/
p.R550C
p.A6E/p.R550C p.A6E/p.R550C p.A6E/p.R550C
Gender Male Male Female Male Male Male Male Male Male
Age 14 years 14 years 12 years 4 monthsy 3 monthsy 6 monthsy 9 daysy 11 monthsy 12 monthsy
HC1 at birth 31.5 cm (2.5 SD) 31 cm (3 SD) 31 cm
(2 SD/3 SD)
30.5 cm
(3.5 SD)
33 cm
(1 SD/2 SD)
32 cm (2 SD) 31.5 cm (2.5 SD) 31 cm (3 SD) 28.5 cm
(1 SD/2 SD)2
Developmental
delay
Severe Severe Severe Severe Severe Severe Severe Severe Severe
Progressive
microcephaly
Yes Yes Yes Yes Yes Yes NA Yes Yes
Epilepsy
Age at onset 1 month 2 weeks 3 weeks None None None 4 days 9 months5 8 days
Type of seizures Spasms, tonic,
myoclonic, GTC3
Spasms, tonic,
myoclonic, GTC3
Spasms, tonic,
myoclonic, GTC3
None None None Tonic, orobuccal Partial complex Partial complex
EEG pattern Hypsarrythmia,
MISF4
Hypsarrythmia,
MISF4
Hypsarrythmia,
MISF4
Disorganized
background
Disorganized
background
Disorganized
background
NA Suppression
bursts, MISF
Suppression
bursts, MISF
Clinical examination
Axial hypotonia No No No No Yes Yes Yes Yes Yes
Appendicular
hypertonia
Yes Yes Yes Yes Yes Yes Yes Yes Yes
Hyperreflexia Yes Yes Yes Yes Yes Yes Yes Yes Yes
Hyperekplexia No No No Yes Yes Yes No No No
Brain MRI
Decreased
cerebral volume
Yes Yes Yes Yes Yes Yes Yes Yes Yes
Decreased size
of pons
No No No Yes Yes Yes Yes Yes Yes
simplified gyri No No No Yes Yes Yes Yes Yes Yes
yDeceased; 1head circumference; 2born at 33.5 weeks of gestation; 3generalized tonic-clonic seizures; 4multiple independent spike foci; 5tremulous movements and abnormal EEG at 4 days;
partial complex seizures with eye deviation and focal epileptic activity at 9 months.
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Figure 2. MRI Images from Family C
(A–D) Sibling C.II.1. Sagittal T1W image (A) performed at 13 days of age reveals decreased size of pons. Axial T2W image (B) reveals prominent pericerebral fluid
spaces surrounding the brain due to volume loss. White matter is diffusely higher in signal intensity than the cortical ribbon, suggesting delayedmyelination. Axial
T1W image (C) confirms lack of bright myelin stripe in the posterior limb of internal capsule (arrow). Three-dimensional computed tomography (D) at 2 months of
age confirms ridge (arrow) from overlapping sutures, palpable at birth. DNA confirmation was not obtained in this infant.
(E–H) Sibling C.II.3. Sagittal T2W image (E) performed at 6 days of age reveals decreased size of pons. Axial T2W image (F) demonstrates prominent pericerebral
fluid spaces surrounding the brain due to volume loss. Axial T1W image (G) confirms lack of myelin stripe in posterior limb of the internal capsule (PLIC). Magnetic
resonance spectroscopy (MRS) TE144 (H) performed in the basal ganglia is age appropriate (as it was in all three siblings).
(I–L) Sibling C.II.4. Sagittal T2W image (I) performed at 1 day of age reveals decreased size of pons. Axial T2W image (J) confirms pericerebral fluid prominence
due to cerebral volume loss in amanner similar to siblings. Axial T1W image (K) shows lack of myelin stripe in PLIC. Diffusion-weighted imaging (DWI) (L) is normal
(as it was in all three siblings).
See also Figure S1.
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ASNS Deficiency Causes Progressive EncephalopathyFamily D is a nonconsanguineous French Canadian family,
consisting of three affected (D.II.1, D.II.2, and D.II.3) and two
unaffected (D.II.4 and D.II.5) siblings (Figure 1A). Exome
sequencing was performed in two affected (D.II.1 and D.II.2)
and two unaffected siblings. In total, 237 rare protein or splice-
altering variants were present in both affected children (with a
frequency %3% in 169 in-house unrelated exomes, 1,000
Genomes Project data set and data from the NHLBI ESP). WeFigure 1. Four Families with ASNS Mutations
(A) Cosegregation of mutations within each of the four families. Filled symbols re
The individuals with a blue star were exome sequenced.
(B) Sanger sequencing confirmation for all threeASNSmutations in the four familie
from a different parent (compound heterozygote).excluded from this list X-linked variants that were also present
in the unaffected male sibling. We also excluded homozygous
or possible compound heterozygous variants that were found
in the same form in at least one unaffected sibling. Only two var-
iants (c.1648C > T/p.R550C; c.17C > A/p.A6E; NM_183356),
both in ASNS, remained after this filtering process (Table S5).
Critically, in all four families there is complete cosegrega-
tion of the identified ASNS mutations/genotypes with diseasepresent known or presumed (in the case of aborted fetus) affected individuals.
s. For family D, Sanger sequencing also confirmed inheritance of eachmutation
Neuron 80, 429–441, October 16, 2013 ª2013 Elsevier Inc. 433
Table 2. Mutations Identified in ASNS
Family Genotype
ASNS
Modification
Nucleotide
Change Ethnicity
Frequency in
Control In-house
Exomes/Genomes
Frequency in
Ancestry-Matched
Controls PolyPhen-2 SIFT
A Homozygous p.F362V c.1084T>G Iranian Jewish 0/261 1/80 Damaging (0.95) Damaging (0.04)
B Homozygous p.F362V c.1084T>G Iranian Jewish 0/261 1/80 Damaging (0.95) Damaging (0.04)
C Homozygous p.R550C c.1648C>T Bangladeshi 0/169 0/225 Damaging (1.00) Damaging (0.01)
D Compound
heterozyous
p.R550C c.1648C>T French Canadian 0/169 0/300 Damaging (1.00) Damaging (0.01)
p.A6E c.17C>A 0/169 0/300 Damaging (0.898) Deleterious (0.02)
Nucleotide and amino acid positions are based on the NCBI Reference sequences NM_183356.3 and NP_899199.2, respectively. See also
Tables S1–S10.
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ASNS Deficiency Causes Progressive Encephalopathy(Figure 1A). Sanger sequencing was used to validate all three
mutations (Figure 1B).
All three missense mutations are predicted to damage the
encoded asparagine synthetase protein by available computer
algorithms (SIFT and PolyPhen-2) and all three mutations are
absent in dbSNP135, the 1,000 Genomes Project data set, and
data from the NHLBI ESP (Table 2). To better estimate the fre-
quency of the p.F362V variant in unaffected individuals, we
directly genotyped this locus in 1,160 additional controls and
failed to detect the mutation. Finally, all three mutations were
genotyped in ancestry-matched controls and all remained
absent (Table 2), with the exception of p.F362V, which has an
estimated carrier frequency of 0.0125 in Iranian Jews.
Additionally, we used the sequence data to test for evidence of
cryptic relatedness between the patient in family A and the
affected siblings from family B and found no indication of
elevated identity by descent beyond what is expected for unre-
lated genomes (data not shown). We also tested whether the
p.F362V ASNS variant is found on a common haplotype in all
affected individuals of Iranian Jewish origin. Indeed, the ASNS
variant was found on the same 1.2 Mb haplotype in both families
and this haplotype was very rare (0.8%) in 261 sequenced con-
trols (Supplemental Experimental Procedures; Table S6). This
observation is consistent with a single founder origin for
p.F362V and subsequent transmission along with the same
extended haplotype. We also did not find evidence for homozy-
gote deletions overlapping the ASNS gene in controls (Supple-
mental Experimental Procedures).
Interestingly, the mutation p.R550C was found in two families
of different ethnic backgrounds. This mutation was associated
with different haplotypes in each of these families, suggesting
that it arose independently. It should be noted that p.R550C cor-
responds to a CpG site, which is associated with a higher muta-
tion rate (Nachman and Crowell, 2000), possibly explaining the
recurrence of this rare mutation in different populations.
Functional Impact of the Nonsynonymous Mutations
To test the effect of the identified mutations on ASNSmRNA and
protein levels, we generated full-length mutant cDNA constructs
(p.A6E, p.F362V, and p.R550C) using PCR-mediated site-
directed mutagenesis (Figure S2). We then transfected both
wild-type and mutant alleles into HEK293 and COS-7 cells and
found similarly robust levels of expression of the mRNA corre-434 Neuron 80, 429–441, October 16, 2013 ª2013 Elsevier Inc.sponding to wild-type and all three mutant alleles (Figure 3A).
This result indicates that these mutations do not overtly affect
mRNA levels, suggesting that they do not influencemRNA stabil-
ity. For the p.F362V mutation, we also compared wild-type and
mutant full-length transcripts, from the patient fibroblasts, to
detect any differences in alternative splicing or exon skipping
and found no evidence for alternately spliced transcripts (data
not shown).
We used two approaches to detect the ASNS protein in trans-
fected cells. First, we used an antibody to human ASNS (Fig-
ure S2). This antibody cross-reacted to produce nonspecific
bands and thus we also used C-terminal FLAG-tagged forms
of ASNS to detect the wild-type and all three mutant forms of
ASNS (Figure S2) using the anti-FLAG antibody. We found that
while high levels of the wild-type protein were easily detected,
a dramatic reduction in protein abundance was seen in the
HEK293 cells expressing the p.A6E or p.F362V mutant allele.
In contrast, cells expressing the p.R550C mutant allele had an
increased level of protein abundance compared to wild-type
(Figure 3B). Consistent with the former observation, a dramatic
reduction in ASNS abundance was observed in patient fibro-
blasts from individual II.1 in family A, harboring the p.F362V allele
(Figure S2). This pattern of protein abundance was also
observed in COS-7 cells transfected with empty, wild-type, or
mutant vectors (Figure S2). These results suggest that these mu-
tations impair ASNS gene function by either reducing protein
expression (p.A6E or p.F362V) or reducing functional perfor-
mance (p.R550C). The mechanism through which the R550C
mutation reduces activity remains to be elucidated, but the clin-
ical similarity in presentation of patients suggests that all muta-
tions are loss of function mutations.
We then asked whether these mutations destabilize the pro-
tein, targeting it for degradation. We blocked both the ubiqui-
tin-proteasome and the macroautophagy pathways, but neither
of these altered ASNS protein abundance (data not shown). We
also used Leupeptin to inhibit lysosomal-dependent degradation
and this also failed to rescue the p.A6E or p.F362V mutant pro-
teins to wild-type levels (Figure 3B), although some experiments
did show a trend toward rescue (data not shown).
ASNS encodes the glutamine-dependent asparagine synthe-
tase enzyme (EC 6.3.5.4), which catalyzes ammonia transfer
from glutamine to aspartic acid via a b-aspartyl-AMP intermedi-
ate. Concordant with this biochemical function, we found that
Figure 3. Functional Impact of ASNS
Mutations
(A) RT-PCR to detect ASNS mRNA expression in
COS-7 cells transfected with empty, wild-type, or
mutant vectors.
(B) Western blots detecting ASNS-FLAG protein
abundance, with or without Leupeptin treatment,
in the HEK293 transfectants using an anti-FLAG
antibody. b-actin was used as a loading control.
See also Figure S2.
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individuals (C.II.3 and D.II.1), whereas glutamine and aspartic
acid, both precursors in the ASNS-catalyzed synthesis of aspar-
agine, weremildly elevated in the patients from family B (Table 3).
These findings are consistent with our in vitro functional studies,
emphasizing that the identified mutations have phenotypic
consequences.
The mutated amino acid residues in ASNS are located within
regions of high sequence conservation among orthologs, from
bacterium to man (Figure 4A), indicating that these amino acids
are likely to be critical for protein function. This is further sup-
ported by the inferred positions of the human ASNS mutations
in the folded bacterial ortholog (Figure 4B; Supplemental Exper-
imental Procedures).
ASNS Expression in the Brain
Cells are capable of both nutritional intake and endogenous syn-
thesis of asparagine, suggesting that ASNSmay be dispensable,
and raising the question of how loss of ASNS protein or its
dysfunction results in a severe, tissue-specific phenotype.
ASNS is under complex transcriptional regulation (Chen et al.,
2004; Greco et al., 1989; Li et al., 2006; Richards and Kilberg,
2006) and is expressed at low levels in most tissues but is highly
expressed in the adult brain, with evidence for a brain-specific
splice variant(s) (Figure S3) (Hongo et al., 1996). Consistent
with this expression pattern, Asns is expressed in the adult
mouse brain (Allen Brain Atlas). In situ hybridization shows that
Asns is also expressed in the developing embryonic mouse brain
(E14.5), is particularly enriched in the cortical plate where theNeuron 80, 429–441,neurons reside, and is also expressed in
the ventricular and subventricular zone
layers (VZ and SVZ) lining the ventricles
of the cerebral cortex, where neural pro-
genitors reside (Figure S3) (Visel et al.,
2004). RNA-seq of E14.5 cortices also
confirms this pattern of expression in the
cortical plate and VZ (Ayoub et al.,
2011). This expression pattern is similar
to that of known microcephaly genes
(Bond et al., 2002; Jackson et al., 2002),
consistent with a role for Asns in cortical
development and brain size.
Asns Gene-Trap Mice
We obtained genetically modified mice
from EUCOMM in which the Asnsgenomic locus contains a gene-trap insertion in intron 2
(ENSMUST00000115542) containing a splice acceptor site
and the LacZ gene (B6NTac;B6N-Asnstm1a(EUCOMM)Wtsi/H,
termed Asns/; Figure S4).
Gene traps are frequently hypomorphs, as there can be
splicing that skips over the gene-trap cassette, but the degree
to which this splicing occurs is construct and gene specific
(Adams and van der Weyden, 2008). To determine the extent
of Asns expression in the Asns gene-trap mice, we performed
a comprehensive Asns mRNA analysis in the brains (cerebral
hemispheres) of adult Asns+/+, Asns+/, and Asns/ mice (3 to
4 months of age). First, RT-PCR was used to semiquantitatively
assess the existence of Asns mRNA transcripts. RT-PCR span-
ning from the second exon to the last exon (exon 12) revealed a
single band the size of the expected wild-type Asns transcript in
all three genotypes (Figure S4). These bands were gel purified
and Sanger sequenced, which confirmed that the wild-type tran-
script was present in all three genotypes and no aberrant splicing
events were observed. Additionally, Gapdh RT-PCR was per-
formed as an internal control and the homozygous mice show
a decreased abundance of the wild-type Asns transcript
compared to the wild-type mice (Figure S4). To quantify this
difference, we performed quantitative real-time TaqMan PCR
using a probe spanning exons seven and eight. ThemRNA levels
were significantly different between the three genotypes (one-
way ANOVA; p < 0.00001) (Figure 5A). A post hoc two-tailed
t test revealed that both mutant genotypes were significantly
different from wild-type mRNA levels (PAsns(+/+)-Asns(+/) =
0.00001, *PAsns(+/+)-Asns(/) < 0.00001) and significantly differentOctober 16, 2013 ª2013 Elsevier Inc. 435
Table 3. Measurements of Amino Acid Concentrations in Patient Blood and Urine
Plasma Amino Acid Levels Urine Amino Acid Levels
Glutamine Aspartate Asparagine Glutamine Aspartate Asparagine
B.II.2 1,250 (254–823 mmol/l) 18 (1–24 mmol/l) 57 (23–112 mmol/l) 382 (20–112 mmol/
mmol creatinine)
36 (1–10 mmol/mmol
creatinine)
21 (0–24 mmol/mmol
creatinine)
B.II.4 1,149 (254–823 mmol/l) 2 (1–24 mmol/l) 49 (23–112 mmol/l) 57 (20–112 mmol/
mmol creatinine)
40 (1–10 mmol/mmol
creatinine)
4 (0–24 mmol/mmol
creatinine)
C.II.1 NA 7 (17–21 mmol/l) NA NA NA NA
C.II.3 NA NA 12 (16–21 mmol/l) NA NA NA
C.II.4 NA 12 (0–20 mmol/l) NA NA NA NA
D.II.1 439 (474–736 mmol/l) 7 (4–18 mmol/l) 11 (31–56 mmol/l) NA NA NA
D.II.2 668 (474–736 mmol/l) 9 (4–18 mmol/l) 55 (31–56 mmol/l) NA NA NA
Data were not available for all fields in all patients (NA). The reference concentrations are indicated within parentheses. See also Table S11.
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to determine whether there was differential expression of the
Asns protein, due to lack of quality and specific mouse anti-
Asns antibodies. These data demonstrate that the Asns gene-
trap mouse is a hypomorph with 20% of the normal level of
Asns mRNA being expressed. Given that two of the human mu-
tations lead to decreased protein expression, this mouse pro-
vides a reliable model for this phenotype.
We next analyzed the brains of Asns/ and control (Asns+/+ or
Asns+/) littermates from embryos and adults. We obtained cor-
onal sections from postnatal day (P) 0 brains and measured
cortical area, cortical thickness, and lateral ventricle area for
each mouse using rostral-caudal-matched sections (using
anatomical landmarks). We found that the cortical thickness
and area of the Asns/ brains were, on average, 14% thinner
and 5% smaller than their control littermates, respectively.
Additionally, the lateral ventricle area in the Asns/ mice was
significantly larger than their control littermates (p = 0.019;
Figure S4).
Due to the progressive nature of the human disorder, we next
evaluated whether adults showed exacerbated brain defects.
We generated paraffin-embedded coronal sections from P84
brains of Asns/ and Asns+/ littermates (three of each geno-
type) (representative sections shown in Figure S4). The use of
heterozygous animals was considered suitable because human
carriers of ASNS mutations remain unaffected. We analyzed
rostral-caudal-matched sections (using anatomical landmarks)
from each animal for several parameters. Measurement of the
cortical surface area, using methods described by Pulvers and
colleagues (Pulvers et al., 2010), showed an 8% reduction in
cortical surface area of Asns/ mice (Figure 5B). A similar
reduction (5%) was observed in the whole-brain surface area
of Asns/ mice (Figure 5C). We also observed that the Asns/
 brains had increased lateral ventricles (95%) relative to con-
trol brains (Figure 5D). Importantly, the cortical thickness of the
Asns/ mice was significantly reduced compared to the
Asns+/ mice (p = 0.022; Figure 5E).
Asns+/ and Asns/ mice were assessed with age-matched
B6NTac control animals in four behavioral assays. We found
no genotype-associated differences in spontaneous locomotor
activity, performance on the rotorod, or anxiety-like behavior in
the light-dark emergence test; however, Asns+/mice were defi-436 Neuron 80, 429–441, October 16, 2013 ª2013 Elsevier Inc.cient and Asns/ mice were severely impaired in short- and
long-term memory in the novel object recognition task (Supple-
mental Experimental Procedures; Figure S5).
Careful observations of mice during behavioral testing
revealed no evidence of seizure activity. To examine the pos-
sibility that Asns/ mice might display epileptiform activity, we
conducted prolonged video electroencephalogram (EEG)
recordings in chronically implanted Asns/ mice (n = 2) and
a wild-type (WT) control (n = 1). Neither behavioral nor
electrographic seizures were detected in Asns/ mice or the
WT controls.
Taken together, these data indicate that this Asns
mouse model recapitulates the human brain phenotype, partic-
ularly in the reduced cortical thickness and increased lateral
ventricle area.
DISCUSSION
We report that mutations in asparagine synthetase (ASNS) cause
a distinct neurodevelopmental disorder characterized by
congenital microcephaly, profound intellectual disability, and
progressive cerebral atrophy. We found that two of these muta-
tions reduce the abundance of the protein. Finally, we have
shown that disrupting this gene in mice creates a model that
mimics aspects of the human phenotype, including structural
brain abnormalities and learning deficits, albeit with what
appears to be a generally milder presentation than observed in
humans.
Studies performed on cancer cells showed that asparagine
depletion affects cell proliferation and survival (reviewed in
Richards and Kilberg, 2006). This is classically illustrated by
the effect of asparaginase administration in childhood acute
lymphoblastic leukemia. Asparaginase delivery to the blood-
stream results in asparagine depletion causing a rapid efflux of
cellular asparagine, which is also destroyed. Most cells express
sufficient ASNS to counteract this asparagine starvation and sur-
vive, but not leukemic cells. Similarly, loss of ASNS activity in
thermosensitive mutant BHK cells leads to cell-cycle arrest as
a consequence of a depletion of cellular asparagine (Greco
et al., 1989; Li et al., 2006).
During development, Asns is expressed in regions where
both neural progenitors and postmitotic neurons are present,
AB
Figure 4. Location and Conservation of Mutated Residues in the
ASNS Gene
(A) A multiple alignment of human ASNS and selected orthologs. Only the
regions harboring mutations are shown. On top: ‘‘*’’ represents identical po-
sition; ‘‘:’’ represents conserved substitutions; ‘‘.’’ represents semiconserved
substitution. Color code is for amino acid type: red, negative; blue, positive;
green, polar; yellow, aliphatic; orange, aromatic; brown, helix breaker.
(B) The structure of E. coli glutamine-dependent asparagine synthetase B
(protein databank ID 1CT9), a bacterial ortholog of human ASNS (A). The
N-terminal glutamine aminotransferase domain is colored in pink, and the
C-terminal asparagine synthase domain is colored in blue. The residues in-
ferred to be equivalent to the mutated A6E and F362V are highlighted in yellow
and the approximate location of the mutated R550C is shown with an asterisk
(crystallography could not be determined for the distal end of C-terminal
domain). Also, the AMP and glutamine molecules are shown in space-filling
style.
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tions. A subset of the brains from our subjects had simplified gyri.
Similar features were found in the mutant mice, which showed
decreased cortical thickness and enlarged lateral ventricles.
These structural abnormalities could be caused in part by aber-
rations in neural progenitor proliferation during development,
resulting from decreased asparagine levels. Asparagine deple-
tion could also cause increased cell death in postmitotic neurons
or glial cells, contributing to the progressive atrophy of the brain
observed in our subjects.
Strikingly, ASNS deficiency causes severe neurological
impairment, without any involvement of peripheral tissues. The
concentration of asparagine in the cerebrospinal fluid (CSF) of
humans is only 10% of the concentration found in plasma(Scholl-Bu¨rgi et al., 2008). The poor transport of asparagine
across the blood-brain barrier suggests that the brain depends
on local de novo synthesis, explaining why the phenotype is
essentially neurological.
In addition to ID, a subset of our patients presented with fea-
tures of hyperexcitability (including epilepsy and hyperekplexia).
These features suggest a mechanism that is consistent with the
accumulation of aspartate/glutamate in the brain, resulting in
enhanced excitability and neuronal damage. While seizures in
the patients could reflect enhanced excitability, these could
also be secondary to the structural effects of altered prolifera-
tion.We cannot exclude the possibility that multiple mechanisms
may be contributing to the observed human phenotype. Further
analyses of animal and cellular models will help to elucidate the
function of ASNS in normal brain development.
Of particular interest is the observation thatAsns hypomorphic
mice appear to have a milder phenotype than the humans with
regards to more modest structural effects on the brain and no
evidence of seizures. The ratio for the concentration of aspara-
gine in the CSF to plasma in rats (0.26) (Nishimura et al., 1995)
appears to be slightly elevated compared to that of humans
(0.081 [Akiyama et al., 2012] to 0.118 [Scholl-Bu¨rgi et al.,
2008]). Assuming that the CSF/plasma ratio is similar in mouse
and rat, this suggests that the concentration of asparagine is
increased in the CSF and interstitial fluid (ISF) of mouse/rat as
compared to humans. Thus, asparagine may be more readily
available to the Asns/ mice due to some physiological differ-
ence between humans and mice, such as transport at the
blood-brain barrier. Alternately, it is possible that low levels of
Asns expression in these mice result in a less severe phenotype.
It will be of great interest to compare the hypomorph to a com-
plete Asns null animal, which may show an even more dramatic
phenotype.
With this report, ASNS deficiency becomes the third example
of a recently recognized group of conditions resulting from the
inability to synthesize a nonessential amino acid. These condi-
tions all feature severe congenital encephalopathy with micro-
cephaly. The others are glutamine synthetase deficiency
(Ha¨berle et al., 2005) and the serine biosynthetic disorders (van
der Crabben et al., 2013). Although knowledge of ASNS defi-
ciency and of other inborn errors of nonessential amino acid
synthesis is incomplete, general considerations regarding diag-
nosis, disease mechanism, and treatment are in order. In almost
every respect, the clinical approach to these diseases is pre-
dicted to be the opposite of that recommended for classical ami-
noacidopathies, which are caused by deficient breakdown of
essential amino acids.
Strikingly, every diagnosis of ASNS deficiency was made by
molecular genetics, despite extensive previous evaluation of
patients that in several cases included amino acid chromatog-
raphy of plasma and CSF. Why was ASNS deficiency not sus-
pected on these grounds? The answer may lie in a combination
of technical considerations and biology. Compared to most
amino acids, the normal levels of asparagine are low, both in
plasma (e.g., 50.7 ± 17.7 mmol/l, in children 0–3 years old) and
CSF (e.g., 4.0 ± 2.9 mmol/l) (Akiyama et al., 2012; Scholl-Bu¨rgi
et al., 2008). For many reasons, low levels of a metabolite may
be less evident than increases. Abnormally low levels are moreNeuron 80, 429–441, October 16, 2013 ª2013 Elsevier Inc. 437
Figure 5. Asns-Deficient Mice and Struc-
tural Brain Abnormalities
(A) Detection of Asns mRNA (qRT-PCR) in the
mouse brain. Four mice of each genotype were
used (all 3–4 months of age). The expression dif-
ferences between the three genotypes are signifi-
cant (one-way ANOVA test *p < 0.00001). A post
hoc two-tailed t test revealed both mutant
genotypes were significantly different from wild-
type expression (PAsns(+/+)-Asns(+/) = 0.00001,
*PAsns(+/+)-Asns(/) < 0.00001) and significantly
different from each other (*PAsns(+/)-Asns(/) =
0.00083). Error bars represent SEM.
(B–E) Measurements of adult mouse brain (P84)
coronal sections, analyzed using ImageJ software
(Schneider et al., 2012), comparing three homo-
zygous mutants to heterozygous littermates. (B)
Cortical surface area as measured in Pulvers et al.
(2010). (C) Surface area of the left hemisphere
of the brain section, (D) surface area of the
lateral ventricle in the left hemisphere of the
brain section, and (E) cortical thickness measured
from the edge of the hippocampus to the outer
cortex. Asterisk (*) indicates a significant differ-
ence by an unpaired t test (p = 0.022). Error bars
represent the range of the observed data.
See also Figures S3, S4, and S5.
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nutrition (which is difficult to standardize in ill newborns or in-
fants) and to machine performance in diagnostic laboratories.
In fact, currently used diagnostic technologies cannot discrimi-
nate low from normal CSF asparagine levels. In summary, results
to date suggest that in patients with unexplained congenital
encephalopathy with microcephaly, the absence of a low value
does not exclude ASNS deficiency. In the future, an enzyme
assay may play an important role in the complete diagnostic
evaluation of patients suspected of ASNS deficiency but experi-
ence is too limited to conclude. In childrenwith severe congenital
encephalopathy and microcephaly, ASNS deficiency should be
considered, and molecular diagnosis is the only method with
proven reliability.
All three known deficiencies of amino acid biosynthesis pre-
sent mainly with neurological features. In these conditions, the438 Neuron 80, 429–441, October 16, 2013 ª2013 Elsevier Inc.deficient amino acid becomes essential.
Hence, an obvious first consideration
for therapy is dietary supplementation,
to provide the deficient amino acid to
the brain. Plasma levels can usually be
substantially increased by dietary sup-
plementation and despite the complex
transport systems for amino acids at
the brain endothelium, a therapeutic
benefit of supplementation has been re-
ported in serine biosynthetic disorders
and glutamine synthetase deficiency
(van der Crabben et al., 2013; Ha¨berle
et al., 2012). Supplementation with
asparagine therefore seems reasonablein ASNS deficiency. However, the prenatal onset of the
microcephaly and the early postnatal presentation raise the
possibility that such treatment will not be curative unless started
prenatally.
The Asns mouse we have analyzed here will provide a model
for future comprehensive exploration of the factors influencing
phenotypic severity. Comparing this hypomorphic mouse model
with a null mouse model will allow us to directly evaluate how re-
sidual levels of ASNS activity comparewith the absence of ASNS
activity, which may inform us about differences in clinical pre-
sentation. We can also utilize both animal models when testing
the effects of dietary supplementation, which would ensure
that a range of ASNS activities were represented, thus covering
the full range of ASNS activities that may also occur in patients.
This work therefore sets the stage for evaluation of treatment op-
tions in Asns mouse models.
Neuron
ASNS Deficiency Causes Progressive EncephalopathyEarly diagnosis of ASNS deficiency is now possible. Careful
clinical observations and studies of Asns-deficient mice will
help define the clinical spectrum and resolve central unanswered
issues regarding the pathophysiology of this condition.
EXPERIMENTAL PROCEDURES
Recruitment of Subjects and Collection of Samples
Families A and B were recruited at Sheba and Wolfson Medical Centers in
Israel, family C at The Hospital for Sick Children in Toronto (Canada), and
family D at Sainte-Justine Hospital in Montreal (Canada). Blood samples
were obtained from most affected individuals, their unaffected siblings, and
their parents. The relevant Institutional Review Boards approved the studies
and appropriate family members gave written consent.
Sequencing and Variant Identification
Exome Sequencing in Families A and B
The Illumina Genome Analyzer IIx platform (Illumina) was used to perform
exome sequencing of the three sequenced microcephaly patients (Figure 1,
family A: II.1 and family B: II.2 and II.4) at the Center for Human Genome
Variation (CHGV) at Duke University, Durham, NC. Prior to sequencing, target
regions were captured using the SureSelect Human All Exon technology
(Aligent Technologies). This technology captures consensus coding sequence
exonic regions and flanking intronic regions totaling38 Mb of genomic DNA.
The resulting short-sequence reads were aligned to the reference genome
(NCBI human genome assembly build 36; Ensembl core database release
50_361 [Hubbard et al., 2009]) using the Burrows-Wheeler Alignment (BWA)
tool (Li and Durbin, 2009). After accounting for PCR duplicates (removed using
the Picard software: http://picard.sourceforge.net) and reads that did not align
to captured regions of the reference genome, the average coverage for these
three samples was713 and each sample had >95% of the bases covered. A
base within the 37.8 Mb captured region was defined as covered ifR5 short
reads spanned this nucleotide (Table S10).
Genetic differences between each patient genome and the reference
genome were identified using the SAMtools variant calling program (Li et al.,
2009), which identifies both single-nucleotide variants (SNVs) and small indels.
We then used the SequenceVariantAnalyzer software (SVA) (Ge et al., 2011) to
annotate all identified variants. SVA was also used to apply quality control fil-
ters to the variants identified by SAMtools. High-quality SNVs were obtained
using the following criteria: consensus score R20, SNP quality score R20,
and reads supporting SNP R3. High-quality indels were obtained using the
following criteria: consensus score R20, indel quality score R50, ratio of
(reads supporting variant/reads supporting reference): 0.2–5.0, and reads sup-
porting indelR3.
Exome Sequencing in Families C and D
The exomes of one of the individuals of family C (II.3) and four individuals of
family D (II.1, II.2, II.4, and II.5) were captured using the Agilent SureSelect
all exon kit V3 (approximately 51.9 Mb of target sequences) and then
sequenced in pair ends (23 100 bp) on the Illumina HiSeq2000 (v3 chemistry;
3 exomes/lane format) at the McGill University Genome Quebec Innovation
Center (Montreal, Canada). The sequences were aligned and the variants
were called using GATK (DePristo et al., 2011). After removal of duplicate
reads, using Picard, we obtained an average coverage of >803 per target
base, with 95% of the target bases being covered at R103. Only variants
that meet all the following criteria were considered: base coverage R83,
reads supporting the variantR3, and ratio of reads supporting variant/reads
supporting reference R20%. Variants were then annotated using Annovar
(Wang et al., 2010).
Genotyping p. F362V
Genotyping of the p.F362V variant in 1,160 controls was performed in the
Center for Human Genome Variation at Duke University (Durham, NC). This
was done using a custom TaqMan genotyping assay (Applied Biosystems):
forward: 50-CCTGCGTAAGTTCATCTGATCCTT-30; reverse: 50-GTATATTCG
GAAGAACACAGATAGCGT-30; probe: 50-TCCAGAGA[A/C]GATCACC-30.
Genotyping of the p.F362V variant in 80 Iranian Jewish controls and the non-
exome-sequenced family members (Figure 1; family A: I.1, I.2, II.2, II.3, and II.4and family B: I.1, I.2, II.1) was performed at the Gertner Institute of Human
Genetics, Sheba Medical Center, Israel. Sanger Sequencing (Figure 1B) or
restriction digest with the restriction enzyme Alw26I (data not shown) were
used to perform this genotyping. Both methods used the following custom
primer sequences: forward: 50-CTTTCAATTATTTCCAAAAATCAAATC-30 and
reverse: 50-CACTGTCATACTGAAAGATGATAGAAA-30. These primers re-
sulted in a 286 bp amplicon that targeted the nucleotide of interest.
The p.F362V variant, found in families A and B, was validated in these three
samples using all three methods: TaqMan genotyping, Sanger sequencing,
and restriction digestion.
Genotyping p.R550C and p.A6E in FrenchCanadian andBangladeshi
Controls
Sanger sequencing of PCR-amplified products was used to genotype
p.R550C and p.A6E variants. The following custom primers were used
for p.A6E: forward: 50-GCCGGTTGAATGTAGAGGTC-30 and reverse: 50-
CCAAAGCAGCAGTTGGTGTA-30. The following custom primers were used
for p.R550C: forward: 50-GCCATTTTAAGCCATTTTGC-30 and reverse: 50-
TTTCCCTTTTCCTAGCTTACCC-30. The mutations p.R550C and p.A6E were
genotyped in 300 French Canadian healthy controls. In addition, p.R550C
was genotyped in 225 Bangladeshi healthy controls.
Clone Preparations
Full-length cDNA encoding human ASNS was amplified from first-strand
cDNA derived from the HEK293 human kidney cell line with an RNeasy plus
mini kit (QIAGEN), High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems), Phusion HF DNA polymerase (Finnzymes), and a specific
primer set (50-CTCGAGATGTGTGGCATTTGGGCGCT-30 and 50-CTCGAGCC
TAAGCTTTGACAGCTGACT-30). The cDNAwas subcloned into the pCR-Blunt
II-TOPO vector (Invitrogen-Life Technologies) and subjected to sequence
analysis (pCR-Blunt II-ASNS-WT). Using pCR-Blunt II-ASNS-WT, A6E,
F362V, and R550C of ASNSwere made by PCR-mediated site-directed muta-
genesis using Phusion HF DNA polymerase and a specific primer set (A6E: 50-
GCTGTTTGGCAGTGATGATTG-30 and 50-TCCCAAATGCCACACATCTC-30;
F362V: 50-GTCTCTGGAGAAGGATCAGA-30 and 50-GATCACCACGCTATC
TGTGT-30; R550C: 50-GCACGCTGACCCACTAC-30 and 50-AGGCAGAAG
GGTCAGTGC-30), which were phosphorylated by T4 polynucleotide kinase
(New England BioLabs). The amplicons were self-ligated using T4 DNA ligase
(Promega) and subjected to sequence analysis (pCR-Blunt II-ASNS-A6E,
pCR-Blunt II-ASNS-F362V, and pCR-Blunt II-ASNS-R550C). ASNS human
cDNA containing each allele was subcloned into the pcDNA3.1(+) vector
(Invitrogen-Life Technologies) using the KpnI and XbaI sites from pCR-
Blunt II-ASNS-WT, pCR-Blunt II-ASNS-A6E, pCR-Blunt II-ASNS-F362V,
or pCR-Blunt II-ASNS-R550C and subjected to sequence analysis
(pcDNA3.1(+)-ASNS-WT, pcDNA3.1(+)-ASNS-A6E, pcDNA3.1(+)-ASNS-
F362V, or pcDNA3.1(+)-ASNS-R550C; Figure S2).
Using pcDNA3.1(+)-ASNS-WT, pcDNA3.1(+)-ASNS-A6E, pcDNA3.1(+)-
ASNS-F362V, or pcDNA3.1(+)-ASNS-R550C, FLAG-tagged-modified ASNS
was made by two-step PCR-mediated site-directed mutagenesis using
Phusion HF DNA polymerase and specific primer sets (first step: 50-GACAAG
TAGGCTCGAGAAGGG-30 and 50-GTAGTCAGCTTTGACAGCTGAC-30; sec-
ond step: 50-GACGATGACAAGTAGGCTCGAGAAGGG-30 and 50-GTCCTTG
TAGTCAGCTTTGACAG-30), which were phosphorylated by T4 polynucleotide
kinase, the amplicons were self-ligated using T4 DNA ligase and subjected to
sequence analysis (pcDNA3.1(+)-ASNS-FLAG-WT, pcDNA3.1(+)-ASNS-
FLAG-A6E, pcDNA3.1(+)-ASNS-FLAG-F362V, or pcDNA3.1(+)-ASNS-FLAG-
R550C). cDNAs encoding FLAG-tagged human ASNS were subcloned into
pcDNA3.1(+) vector again, using the KpnI and XbaI sites and subjected to
sequence analysis (Figure S2).
Cell Culture: RT-PCR
Empty pcDNA3.1 (+) vector, pcDNA3.1(+)-ASNS wild-type, or pcDNA3.1(+)-
ASNS mutant (p.F362V, p.R550C, or p.A6E) were transfected into the monkey
COS-7 kidney cell line or human HEK293 kidney cells by lipofection using
Lipofectamine 2000 (Invitrogen-Life Technologies). Total RNA was extracted
from transfectants using an RNeasy plus mini kit, and first-strand full-length
cDNA encoding human ASNS was synthesized using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems). RT-PCR to detect
ASNS mRNA expression was performed in 25 cycles at 96C for 30 s, 60C
for 30 s, and 72C for 30 s using AmpliTaq Gold DNA polymerase (AppliedNeuron 80, 429–441, October 16, 2013 ª2013 Elsevier Inc. 439
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and 50-CACCTTTCTAGCAGCCAGTA-30) (Figure 3A).
Cell Culture: Western Blotting
Forty-eight hours after transfection, the cells were lysed with RIPA buffer
(Sigma-Aldrich) with Protease inhibitor cocktail (Sigma-Aldrich), and the ly-
sates were subjected to SDS-PAGE gel and transferred to a polyvinylidene di-
fluoridemembrane (Millipore). Themembraneswere incubated with anti-FLAG
M2 monoclonal antibody (Sigma-Aldrich) or anti-actin antibody (Santa Cruz
Biotechnology). Proteins were visualized with the ECL plus western blotting
detection system (GE Healthcare). For Leupeptin treatment, 24 hr posttrans-
fection, the cells were incubated with 100 mM Leupeptin (Sigma Aldrich). After
8 hr incubation with Leupeptin, the cells were lysed, and FLAG-tagged ASNS
were detected as above.
Protein Conservation
Species and ASNS proteins were from gi P08243 (Human, Homo sapiens),
ENSMUSP00000031766 (mouse, Mus musculus), ENSGALP00000015846,
(chicken, Gallus gallus), ENSACAP00000012780 (lizard, Anolis carolinensis),
ENSXETP00000054608, (frog, Xenopus tropicalis), ENSTRUP00000013503
(fish, fugu, Takifugu rubripe), FBpp0089009 (fruit fly,Drosophilamelanogaster),
NP_741864 (worm, nematode, Caenorhabditis elegans), YGR124W (yeast,
Saccharomyces cerevisia), and YP_003233213.1 (bacterium, Escherichia
coli) (Figure 4A). Sequence alignment was performed using ClustalW (Thomp-
son et al., 2002) and alignment editing with the BioEdit software (http://www.
mbio.ncsu.edu/bioedit/bioedit.html).
The pdb structure was made using Discovery Studio program (http://
accelrys.com/products/discovery-studio) (Figure 4B).
Mouse Analyses
Asnsmicewere obtained from the Eucommconsortium.Miceweremaintained
by breeding to C57BL/6NTac. Histology at P0 was performed by cryopreser-
vation of tissue, cryosectioning, and hematoxylin and eosin staining. Histology
in adult brains was performed by fixation of tissue using formalin perfusion. Tis-
sue was sent to http://www.histoserv.com for paraffin embedding, sectioning,
and staining. Analysis of area and thickness was performed by quantifying
measurements using ImageJ. The p values for structural measurements
were obtained using an unpaired t test and calculations were done using R.
cDNA
Mouse cerebral hemispheres were carefully dissected. Total RNA was ex-
tracted from brain tissue using an RNeasy plus mini kit, and first-strand full-
length cDNA encoding human ASNS was synthesized using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems).
Quantitative Real-Time RT-PCR
Quantitative real-time PCR was done using an Asns gene expression assay,
with FAM reporter, spanning exons 7–8 (Mm00803785_m1; Life Technologies)
and a Gapdh gene expression assay with VIC reporter (Mm99999915_g1; Life
Technologies). Samples were run in triplicate and the standard curve was
made using cDNA from a nontest wild-type sample. Twelve mice between 3
and 4 months of age were used for qPCR. Four mice of each genotype were
used (Asns+/+, Asns+/, and Asns/). One-way ANOVA was used to assess
expression differences between the three genotypes (p < 0.00001). A post
hoc two-tailed t test was then used to assess genotypic differences in expres-
sion (PWT-Asns
+/ = 0.00001, *PWT-Asns
/ < 0.00001, *PAsns
+/
-Asns
/ =
0.00083).
Regular RT-PCR
RT-PCR to detect AsnsmRNA expression was performed in 35 cycles at 96C
for 30 s, 58C for 30 s, and 72C for 90 s using AmpliTaqGold DNA polymerase
(Applied Biosystems) and a specific primer set (50-CAGTGTCTGAGTGCGAT
GAAGA-30 and 50-GCGTTCAAAGATCTGACGGTAG-30) (Figure S4).
RT-PCR to detect Gapdh mRNA expression was performed in 25 cycles at
96C for 30 s, 57C for 30 s, and 72C for 45 s using AmpliTaq Gold DNA
polymerase (Applied Biosystems) and a specific primer set (50-ACCACAGTC
CATGCCATCAC-30 and 50-CACCACCCTGTTGCTGTAGCC-30) (Figure S4).
Western Blotting
Two different antibodies were tried for detection of mouse Asns: anti-human-
ASNS, which recognizes amino acid residues 506–520 of ASNS (Sigma-
Aldrich), and anti-Asns, with species reactivity in mouse, rat, and human,
which recognizes amino acid residues at the C terminus (Abcam). Both were
nonspecific (data not shown).440 Neuron 80, 429–441, October 16, 2013 ª2013 Elsevier Inc.Video EEG Recordings of Mice
Two adult Asns homozygous mice and one age-matched WT mouse were
anesthetized by intraperitoneal injection of Nembutal (60 mg/kg). Under
stereotaxic guidance, four monopolar electrodes were implanted into the sub-
dural space over the left and right parietal cortex and occipital cortex for
chronic EEG recording. After a 7-day postoperative recovery, EEG activity
was recorded with themousemoving freely in a cage for 80 hr; animal behavior
was recorded simultaneously with a digital video camera. The EEG and behav-
ioral activities were analyzed by an individual blinded to mouse genotype.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and 11 tables and can be found with this article online at http://
dx.doi.org/10.1016/j.neuron.2013.08.013.
ACKNOWLEDGMENTS
We would like to thank all four families for their willingness to participate in
this study. J.L.M. is a National Scientist of the Fonds de Recherche du
Que´bec - Sante´. E.K.R. is funded by a predoctoral grant from the Epilepsy
Foundation and the Jo Rae Wright Fellowship for outstanding women in sci-
ence (Duke University). J.M.C.-C. holds a salary award from the Re´seau de
Me´decine Ge´ne´tique Applique´e du Que´bec (RMGA). We acknowledge the
following colleagues for supplying control samples: R. Brown, G. Cavalleri,
L. Cirulli, N. Delanty, C. Depondt, V. Dixon, E. Heinzen, J. Hoover-Fong, A. Hu-
sain, D. Levy, K. Linney, W. Lowe, J. McEvoy, M. Mikati, J. Milner, A. Need, R.
Ottman, R. Radtke, J. Silver, M. Silver, S. Sisodiya, N. Sobriera, D. Valle, and
N. Walley. We wish to thank Katherine Whang for helping to section the mouse
brains. We wish to thank C. Means and T. Rhodes for helping with the behav-
ioral experiments and J. Zhou andC. Elms for breeding, genotyping, andmain-
taining themice.We thank R. Olender and P. Allard for helpful insights.We also
thank the members of the RMGA bioinformatic team (Alexandre Dionne-
Laporte, Dan Spiegelman, Edouard Henrion, and Ousmane Diallo) for the bio-
informatic analysis of the exome sequencing data (families C and D). This
research has been funded in part by federal funds from the Center for HIV/
AIDS Vaccine Immunology (‘‘CHAVI’’) under a grant from the National Institute
of Allergy and Infectious Diseases, National Institutes of Health, Grant Number
UO1AIO67854 to D.B.G., and by the March of Dimes (grant no. 12-FY10-236)
and Canadian Institutes of Health Research (MOP 106499) to J.L.M. Additional
funding provided by: ARRA 1RC2NS070342-01, NIMH Grant RC2MH089915,
NINDS Award RC2NS070344, and the Crown Human Genome Center at the
Weizmann Institute of Science.
Accepted: August 15, 2013
Published: October 16, 2013
REFERENCES
Adams, D.J., and van der Weyden, L. (2008). Contemporary approaches for
modifying the mouse genome. Physiol. Genomics 34, 225–238.
Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A.,
Bork, P., Kondrashov, A.S., and Sunyaev, S.R. (2010). A method and server
for predicting damaging missense mutations. Nat. Methods 7, 248–249.
Akiyama, T., Kobayashi, K., Higashikage, A., Sato, J., and Yoshinaga, H.
(2012). CSF/plasma ratios of amino acids: Reference data and transports in
children. Brain Dev. Published online December 31, 2012. http://dx.doi.org/
10.1016/j.braindev.2012.12.001.
Ayoub, A.E., Oh, S., Xie, Y., Leng, J., Cotney, J., Dominguez, M.H., Noonan,
J.P., and Rakic, P. (2011). Transcriptional programs in transient embryonic
zones of the cerebral cortex defined by high-resolution mRNA sequencing.
Proc. Natl. Acad. Sci. USA 108, 14950–14955.
Bond, J., Roberts, E., Mochida, G.H., Hampshire, D.J., Scott, S., Askham,
J.M., Springell, K., Mahadevan, M., Crow, Y.J., Markham, A.F., et al. (2002).
ASPM is a major determinant of cerebral cortical size. Nat. Genet. 32,
316–320.
Neuron
ASNS Deficiency Causes Progressive EncephalopathyChen, H., Pan, Y.X., Dudenhausen, E.E., and Kilberg, M.S. (2004). Amino
acid deprivation induces the transcription rate of the human asparagine syn-
thetase gene through a timed program of expression and promoter binding
of nutrient-responsive basic region/leucine zipper transcription factors as
well as localized histone acetylation. J. Biol. Chem. 279, 50829–50839.
DePristo, M.A., Banks, E., Poplin, R., Garimella, K.V., Maguire, J.R., Hartl, C.,
Philippakis, A.A., del Angel, G., Rivas, M.A., Hanna, M., et al. (2011). A frame-
work for variation discovery and genotyping using next-generation DNA
sequencing data. Nat. Genet. 43, 491–498.
Ge, D., Ruzzo, E.K., Shianna, K.V., He,M., Pelak, K., Heinzen, E.L., Need, A.C.,
Cirulli, E.T., Maia, J.M., Dickson, S.P., et al. (2011). SVA: software for anno-
tating and visualizing sequenced human genomes. Bioinformatics 27, 1998–
2000.
Greco, A., Gong, S.S., Ittmann, M., and Basilico, C. (1989). Organization and
expression of the cell cycle gene, ts11, that encodes asparagine synthetase.
Mol. Cell. Biol. 9, 2350–2359.
Ha¨berle, J., Go¨rg, B., Rutsch, F., Schmidt, E., Toutain, A., Benoist, J.-F., Gelot,
A., Suc, A.-L., Ho¨hne, W., Schliess, F., et al. (2005). Congenital glutamine defi-
ciency with glutamine synthetase mutations. N. Engl. J. Med. 353, 1926–1933.
Ha¨berle, J., Shahbeck, N., Ibrahim, K., Schmitt, B., Scheer, I., O’Gorman, R.,
Chaudhry, F.A., and Ben-Omran, T. (2012). Glutamine supplementation in a
child with inherited GS deficiency improves the clinical status and partially
corrects the peripheral and central amino acid imbalance. Orphanet J. Rare
Dis. 7, 48.
Hongo, S., Chiyo, T., and Takeda, M. (1996). Cloning of cDNA for asparagine
synthetase from rat Sertoli cell. Biochem. Mol. Biol. Int. 38, 189–196.
Hubbard, T.J.P., Aken, B.L., Ayling, S., Ballester, B., Beal, K., Bragin, E., Brent,
S., Chen, Y., Clapham, P., Clarke, L., et al. (2009). Ensembl 2009. Nucleic
Acids Res. 37(Database issue), D690–D697.
Jackson, A.P., Eastwood, H., Bell, S.M., Adu, J., Toomes, C., Carr, I.M.,
Roberts, E., Hampshire, D.J., Crow, Y.J., Mighell, A.J., et al. (2002).
Identification of microcephalin, a protein implicated in determining the size
of the human brain. Am. J. Hum. Genet. 71, 136–142.
Li, B.S., Gu, L.J., Luo, C.Y., Li, W.S., Jiang, L.M., Shen, S.H., Jiang, H., Shen,
S.H., Zhang, B., Chen, J., et al. (2006). The downregulation of asparagine
synthetase expression can increase the sensitivity of cells resistant to l-aspar-
aginase. Leukemia 20, 2199–2201.
Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with
Burrows-Wheeler transform. Bioinformatics 25, 1754–1760.
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G.,
Abecasis, G., and Durbin, R.; 1000 Genome Project Data ProcessingSubgroup. (2009). The Sequence alignment/map format and SAMtools.
Bioinformatics 25, 2078–2079.
Mahmood, S., Ahmad, W., and Hassan, M.J. (2011). Autosomal Recessive
Primary Microcephaly (MCPH): clinical manifestations, genetic heterogeneity
and mutation continuum. Orphanet J. Rare Dis. 6, 39.
Nachman, M.W., and Crowell, S.L. (2000). Estimate of the mutation rate per
nucleotide in humans. Genetics 156, 297–304.
Ng, P.C., and Henikoff, S. (2003). SIFT: Predicting amino acid changes that
affect protein function. Nucleic Acids Res. 31, 3812–3814.
Nishimura, F., Nishihara, M., Mori, M., Torii, K., and Takahashi, M. (1995).
Excitability of neurons in the ventromedial nucleus in rat hypothalamic slices:
modulation by amino acids at cerebrospinal fluid levels. Brain Res. 691,
217–222.
Pulvers, J.N., Bryk, J., Fish, J.L., Wilsch-Bra¨uninger, M., Arai, Y., Schreier, D.,
Naumann, R., Helppi, J., Habermann, B., Vogt, J., et al. (2010). Mutations in
mouse Aspm (abnormal spindle-like microcephaly associated) cause not
only microcephaly but also major defects in the germline. Proc. Natl. Acad.
Sci. USA 107, 16595–16600.
Richards, N.G.J., and Kilberg, M.S. (2006). Asparagine synthetase chemo-
therapy. Annu. Rev. Biochem. 75, 629–654.
Schneider, C.A., Rasband, W.S., and Eliceiri, K.W. (2012). NIH image to
ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675.
Scholl-Bu¨rgi, S., Haberlandt, E., Heinz-Erian, P., Deisenhammer, F., Albrecht,
U., Sigl, S.B., Rauchenzauner, M., Ulmer, H., and Karall, D. (2008). Amino acid
cerebrospinal fluid/plasma ratios in children: influence of age, gender, and
antiepileptic medication. Pediatrics 121, e920–e926.
Thompson, J.D., Gibson, T.J., and Higgins, D.G. (2002). Multiple sequence
alignment using ClustalW and ClustalX. Curr. Protoc. Bioinformatics Chapter
2, http://dx.doi.org/10.1002/0471250953.bi0203s00, Unit 2.3.
van der Crabben, S.N., Verhoeven-Duif, N.M., Brilstra, E.H., Van Maldergem,
L., Coskun, T., Rubio-Gozalbo, E., Berger, R., and de Koning, T.J. (2013). An
update on serine deficiency disorders. J. Inherit. Metab. Dis. 36, 613–619.
Visel, A., Thaller, C., and Eichele, G. (2004). GenePaint.org: an atlas of gene
expression patterns in the mouse embryo. Nucleic Acids Res. 32(Database
issue), D552–D556.
Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation
of genetic variants from high-throughput sequencing data. Nucleic Acids Res.
38, e164.Neuron 80, 429–441, October 16, 2013 ª2013 Elsevier Inc. 441
